Rapport Therapeutics, Inc. (RAPP): who owns it and who trades it
As of Nov 16, 2026, RAPP insiders reported 72 open-market sales worth $47.2M and 11 purchases worth $22M in the last 12 months, with 1% of the sale value made under pre-set 10b5-1 plans. The largest seller was Third Rock Ventures VI, L.P. (10% owner), with $28.3M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Rapport Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RAPP
162 funds and institutions reported RAPP shares worth $2.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 7.17M | 15.01% | $299M | +0% |
| Trv Gp V, LLC | 6.28M | 13.14% | $262M | -12% |
| ARCH Venture Management, LLC | 3.73M | 7.80% | $155M | No change |
| Capital International Investors | 2.92M | 6.11% | $122M | -6% |
| Goldman Sachs Group Inc | 2.91M | 6.09% | $121M | -1% |
| BlackRock, Inc. | 2.70M | 5.65% | $113M | +8% |
| Cormorant Asset Management, LP | 2.66M | 5.56% | $111M | -10% |
| Sofinnova Investments, Inc. | 1.90M | 3.98% | $79.4M | No change |
| Johnson & Johnson | 1.78M | 3.73% | $74.4M | No change |
| Polar Capital Holdings Plc | 1.61M | 3.37% | $67M | -2% |
| Baker Bros. Advisors LP | 1.55M | 3.24% | $64.5M | No change |
| California State Teachers Retirement System | 1.35M | 2.83% | $32.5M | +3951% |
| Vanguard Capital Management LLC | 1.35M | 2.82% | $56.1M | +2% |
| Trv Gp Vi, LLC | 969,218 | 2.03% | $40.4M | No change |
| State Street Corp | 818,712 | 1.71% | $34.1M | +8% |
| Geode Capital Management, LLC | 793,453 | 1.66% | $33.1M | +10% |
| T. Rowe Price Associates | 787,446 | 1.65% | $32.8M | -9% |
| Perceptive Advisors LLC | 773,342 | 1.62% | $32.2M | +15% |
| Vestal Point Capital, LP | 730,000 | 1.53% | $30.4M | -49% |
| Alliancebernstein L.P. | 693,384 | 1.45% | $21.7M | -5% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RAPP insiders reported $22M of open-market purchases and $47.2M of sales. 1% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | James Healy | Director | Purchase | 952,380 | $21.00 | $20M | Form 4 |
| Oct 28, 2026 | James Healy | Director | Purchase | 6,395 | $21.00 | $134K | Form 4 |
| Oct 28, 2026 | James Healy | Director | Purchase | 3,772 | $21.00 | $79.2K | Form 4 |
| Oct 28, 2026 | James Healy | Director | Purchase | 6,933 | $21.00 | $146K | Form 4 |
| Oct 23, 2026 | Ramiro Sanchez | Director | Purchase | 3,600 | $27.35 | $98.5K | Form 4 |
| Oct 22, 2026 | John Maraganore | Director | Purchase | 8,239 | $26.38 | $217K | Form 4 |
| Oct 22, 2026 | John Maraganore | Director | Purchase | 1,172 | $26.92 | $31.5K | Form 4 |
| Oct 22, 2026 | Steven M Paul | Director | Purchase | 35,714 | $27.28 | $974K | Form 4 |
| Oct 22, 2026 | Wendy B. Young | Director | Purchase | 3,789 | $26.39 | $100K | Form 4 |
| Oct 22, 2026 | Paul M Silva | Director | Purchase | 3,680 | $27.07 | $99.6K | Form 4 |
| Oct 21, 2026 | Abraham Ceesay | CEO | Sale plan | 2,210 | $29.16 | $64.4K | Form 4 |
| Oct 21, 2026 | Troy A. Ignelzi | CFO | Purchase | 5,500 | $26.10 | $144K | Form 4 |
| Oct 7, 2026 | Abraham Ceesay | CEO | Sale plan | 1,147 | $30.66 | $35.2K | Form 4 |
| Oct 6, 2026 | Abraham Ceesay | CEO | Sale plan | 3,375 | $32.03 | $108K | Form 4 |
| Sep 30, 2026 | Cheryl Gault | Chief Operating Officer | Sale plan | 7,925 | $33.04 | $262K | Form 4 |
| Sep 30, 2026 | Cheryl Gault | Chief Operating Officer | Sale plan | 2,075 | $33.76 | $70K | Form 4 |
| Sep 23, 2026 | Abraham Ceesay | CEO | Sale | 43 | $41.05 | $1.8K | Form 4 |
| Sep 23, 2026 | Abraham Ceesay | CEO | Sale | 1,952 | $39.05 | $76.2K | Form 4 |
| Sep 23, 2026 | Abraham Ceesay | CEO | Sale | 215 | $39.86 | $8.6K | Form 4 |
| Sep 8, 2026 | Abraham Ceesay | CEO | Sale | 7,141 | $45.56 | $325K | Form 4 |
| Sep 8, 2026 | Abraham Ceesay | CEO | Sale | 1,069 | $46.01 | $49.2K | Form 4 |
| Aug 25, 2026 | Abraham Ceesay | CEO | Sale | 18,921 | $49.57 | $938K | Form 4 |
| Aug 25, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 16,201 | $51.06 | $827K | Form 4 |
| Aug 25, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 20,799 | $50.31 | $1M | Form 4 |
| Aug 24, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 13,160 | $50.00 | $658K | Form 4 |
| Aug 19, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 404 | $49.90 | $20.2K | Form 4 |
| Aug 11, 2026 | Abraham Ceesay | CEO | Sale | 3,664 | $46.90 | $172K | Form 4 |
| Aug 11, 2026 | Abraham Ceesay | CEO | Sale | 19,500 | $48.04 | $937K | Form 4 |
| Aug 11, 2026 | Abraham Ceesay | CEO | Sale | 5,794 | $48.62 | $282K | Form 4 |
| Aug 10, 2026 | Abraham Ceesay | CEO | Sale | 14,171 | $45.97 | $651K | Form 4 |
| Aug 10, 2026 | Abraham Ceesay | CEO | Sale | 8,370 | $46.75 | $391K | Form 4 |
| Jul 27, 2026 | Abraham Ceesay | CEO | Sale | 2,203 | $42.11 | $92.8K | Form 4 |
| Jul 27, 2026 | Abraham Ceesay | CEO | Sale | 7 | $42.74 | $299 | Form 4 |
| Jul 14, 2026 | Abraham Ceesay | CEO | Sale | 2,729 | $40.57 | $111K | Form 4 |
| Jul 14, 2026 | Abraham Ceesay | CEO | Sale | 5,481 | $39.72 | $218K | Form 4 |
| Jun 30, 2026 | Cheryl Gault | Chief Operating Officer | Sale | 1,000 | $43.15 | $43.1K | Form 4 |
| Jun 30, 2026 | Cheryl Gault | Chief Operating Officer | Sale | 3,308 | $42.17 | $139K | Form 4 |
| Jun 30, 2026 | Cheryl Gault | Chief Operating Officer | Sale | 1,900 | $40.09 | $76.2K | Form 4 |
| Jun 30, 2026 | Cheryl Gault | Chief Operating Officer | Sale | 3,792 | $41.39 | $157K | Form 4 |
| Jun 29, 2026 | Abraham Ceesay | CEO | Sale | 876 | $40.34 | $35.3K | Form 4 |
| Jun 29, 2026 | Abraham Ceesay | CEO | Sale | 7,344 | $39.77 | $292K | Form 4 |
| May 26, 2026 | Third Rock Ventures V, L.P. +5 | 10% owner | Sale | 18,572 | $40.05 | $744K | Form 4 |
| May 11, 2026 | Third Rock Ventures V, L.P. +5 | 10% owner | Sale | 133,618 | $40.24 | $5.4M | Form 4 |
| May 8, 2026 | Third Rock Ventures VI, L.P. +5 | 10% owner | Sale | 5,018 | $40.31 | $202K | Form 4 |
| May 7, 2026 | Third Rock Ventures VI, L.P. +5 | 10% owner | Sale | 271,495 | $40.12 | $10.9M | Form 4 |
| Apr 17, 2026 | Third Rock Ventures VI, L.P. +5 | 10% owner | Sale | 426,005 | $40.32 | $17.2M | Form 4 |
| Apr 17, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 20,225 | $39.99 | $809K | Form 4 |
| Apr 14, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 10,200 | $35.08 | $358K | Form 4 |
| Apr 13, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 9,165 | $34.97 | $321K | Form 4 |
| Apr 10, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 500 | $34.98 | $17.5K | Form 4 |
| Apr 8, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 360 | $34.90 | $12.6K | Form 4 |
| Mar 30, 2026 | Cheryl Gault | Chief Operating Officer | Sale | 7,161 | $28.04 | $201K | Form 4 |
| Mar 30, 2026 | Cheryl Gault | Chief Operating Officer | Sale | 2,839 | $28.55 | $81.1K | Form 4 |
| Mar 25, 2026 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 10,115 | $29.99 | $303K | Form 4 |
| Mar 5, 2026 | Cheryl Gault | Chief Operating Officer | Sale | 2,014 | $28.93 | $58.3K | Form 4 |
| Feb 18, 2026 | Abraham Ceesay | CEO | Sale | 3,552 | $29.05 | $103K | Form 4 |
| Feb 18, 2026 | Abraham Ceesay | CEO | Sale | 2,100 | $29.80 | $62.6K | Form 4 |
| Feb 18, 2026 | Abraham Ceesay | CEO | Sale | 2,983 | $29.04 | $86.6K | Form 4 |
| Feb 18, 2026 | Abraham Ceesay | CEO | Sale | 2,281 | $29.80 | $68K | Form 4 |
| Feb 17, 2026 | David Bredt | Chief Scientific Officer | Sale | 2,200 | $29.59 | $65.1K | Form 4 |
| Feb 17, 2026 | David Bredt | Chief Scientific Officer | Sale | 5,400 | $28.95 | $156K | Form 4 |
| Feb 17, 2026 | David Bredt | Chief Scientific Officer | Sale | 900 | $28.02 | $25.2K | Form 4 |
| Jan 20, 2026 | Abraham Ceesay | CEO | Sale | 5,083 | $26.11 | $133K | Form 4 |
| Jan 20, 2026 | Abraham Ceesay | CEO | Sale | 5,833 | $26.12 | $152K | Form 4 |
| Jan 15, 2026 | David Bredt | Chief Scientific Officer | Sale | 8,300 | $26.83 | $223K | Form 4 |
| Jan 15, 2026 | David Bredt | Chief Scientific Officer | Sale | 200 | $27.40 | $5.5K | Form 4 |
| Dec 31, 2025 | David Bredt | Chief Scientific Officer | Sale | 6,567 | $30.05 | $197K | Form 4 |
| Dec 31, 2025 | Krishnaswamy Yeleswaram | Chief Development Office | Sale | 2,840 | $30.05 | $85.3K | Form 4 |
| Dec 17, 2025 | Abraham Ceesay | CEO | Sale | 2,792 | $30.04 | $83.9K | Form 4 |
| Dec 17, 2025 | Abraham Ceesay | CEO | Sale | 515 | $31.04 | $16K | Form 4 |
| Dec 17, 2025 | Abraham Ceesay | CEO | Sale | 2,421 | $30.04 | $72.7K | Form 4 |
| Dec 17, 2025 | Abraham Ceesay | CEO | Sale | 2,441 | $28.84 | $70.4K | Form 4 |
| Dec 17, 2025 | Abraham Ceesay | CEO | Sale | 600 | $31.04 | $18.6K | Form 4 |
| Dec 17, 2025 | Abraham Ceesay | CEO | Sale | 2,147 | $28.84 | $61.9K | Form 4 |
| Dec 15, 2025 | David Bredt | Chief Scientific Officer | Sale | 7,704 | $29.95 | $231K | Form 4 |
| Dec 15, 2025 | David Bredt | Chief Scientific Officer | Sale | 796 | $30.68 | $24.4K | Form 4 |
| Nov 26, 2025 | Cheryl Gault | Chief Operating Officer | Sale | 5,000 | $30.10 | $150K | Form 4 |
| Nov 17, 2025 | Abraham Ceesay | CEO | Sale | 2,242 | $24.91 | $55.8K | Form 4 |
| Nov 17, 2025 | Abraham Ceesay | CEO | Sale | 3,056 | $25.43 | $77.7K | Form 4 |
| Nov 17, 2025 | Abraham Ceesay | CEO | Sale | 2,777 | $24.92 | $69.2K | Form 4 |
| Nov 17, 2025 | Abraham Ceesay | CEO | Sale | 2,841 | $25.44 | $72.3K | Form 4 |
| Nov 17, 2025 | David Bredt | Chief Scientific Officer | Sale | 5,344 | $25.39 | $136K | Form 4 |
| Nov 17, 2025 | David Bredt | Chief Scientific Officer | Sale | 3,156 | $24.84 | $78.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Third Rock Ventures VI, L.P. | 10% owner | – | $28.3M | May 8, 2026 |
| James Healy | Director | $20.4M | – | Oct 28, 2026 |
| Third Rock Ventures V, L.P. | 10% owner | – | $6.1M | May 26, 2026 |
| Abraham Ceesay | Chief Executive Officer, Director | – | $6M | Oct 21, 2026 |
| Krishnaswamy Yeleswaram | Chief Development Officer | – | $4.5M | Aug 25, 2026 |
| Cheryl Gault | Chief Operating Officer | – | $1.2M | Sep 30, 2026 |
| David Bredt | Chief Scientific Officer | – | $1.1M | Feb 17, 2026 |
| Steven M Paul | Director | $974K | – | Oct 22, 2026 |
| John Maraganore | Director | $249K | – | Oct 22, 2026 |
| Troy A. Ignelzi | Chief Financial Officer | $144K | – | Oct 21, 2026 |
| Wendy B. Young | Director | $100K | – | Oct 22, 2026 |
| Paul M Silva | Director | $99.6K | – | Oct 22, 2026 |
| Ramiro Sanchez | Director | $98.5K | – | Oct 23, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RAPP short interest
Moderate short interest. 8.2% of RAPP shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 64%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.96M RAPP shares were sold short, 8.2% of the shares outstanding, up 29.7% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 1.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.96M | 8.25% | +30% | 2.21M | 1.8 |
| Oct 15, 2026 | 3.05M | 6.36% | -4% | 259,510 | 11.8 |
| Sep 30, 2026 | 3.19M | 6.66% | +42% | 660,098 | 4.8 |
| Sep 15, 2026 | 2.25M | 4.69% | +1% | 284,289 | 7.9 |
| Aug 31, 2026 | 2.23M | 4.66% | +0% | 271,423 | 8.2 |
| Aug 14, 2026 | 2.23M | 4.64% | -1% | 295,758 | 7.5 |
| Jul 31, 2026 | 2.25M | 4.70% | -16% | 299,167 | 7.5 |
| Jul 15, 2026 | 2.69M | 5.63% | +19% | 438,999 | 6.1 |
| Jun 30, 2026 | 2.26M | 4.73% | +1% | 488,981 | 4.6 |
| Jun 15, 2026 | 2.25M | 4.70% | -9% | 316,690 | 7.1 |
| May 29, 2026 | 2.46M | 5.15% | +2% | 284,811 | 8.6 |
| May 15, 2026 | 2.42M | 5.06% | -21% | 348,797 | 6.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Rapport Therapeutics company events
Rapport Therapeutics filed 10 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Oct 30, 2026AgreementRapport Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters, related to an underwritten public offering of (i) 8,333,334 shares of the Company’s common stock, par value… Filing
- Oct 20, 2026AnnouncementThe Company announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 21, 2026AnnouncementThe Company announced results from the 8-week follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures. Filing
- Mar 10, 2026ResultsReleased financial results. Filing
- Jan 7, 2026AnnouncementRapport Therapeutics, Inc. filed a prospectus supplement to the Company’s effective shelf registration statement on Form S-3 (File No. 333-288444). Filing
- Jan 7, 2026AnnouncementThe Company updated its corporate presentation for use in meetings with investors, analysts and others from time to time and made the presentation available on the “Investors” page of the Company’s website at www.rapportrx.com. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Rapport Therapeutics financials
Famous investors that hold RAPP
2 of the 50 well-known investors we track reported holding RAPP in their latest 13F filing. The largest position is Israel Englander's, worth $2.3M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 68,118 | $2.3M | 0.0% | -56% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 15,289 | $514K | 0.0% | -81% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RAPP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G/A | 5.1% |
| Nov 16, 2026 | Cormorant Asset Management, LP | 13G/A | 5.1% |
Questions about Rapport Therapeutics, Inc. (RAPP) stock
Who owns the most RAPP stock?
The largest reported owner of Rapport Therapeutics, Inc. (RAPP) is FMR LLC (Fidelity), with 15.0% of the company. In total, 162 funds and institutions reported holding RAPP at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are RAPP insiders buying or selling?
In the last 12 months, RAPP insiders reported 11 open-market purchases worth $22M and 72 sales worth $47.2M. The latest trade was on Oct 28, 2026. See every trade.
What is the short interest in RAPP?
As of Oct 30, 2026, 3.96M RAPP shares were sold short, 8.2% of the shares outstanding, up 29.7% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 1.8 trading days (days to cover). See the history.
Which famous investors hold RAPP?
2 of the 50 well-known investors we track reported RAPP in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $2.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.